Complex, pharmaceutical composition, vaccine, and applications thereof
The complex enables the production of monoclonal antibodies that recognize dynamic epitopes by presenting glycopeptides on cells without MHC dependency, addressing the challenge of antibody production and improving cancer treatment efficacy.
Patent Information
- Application Number
- PCT/JP2024/017786
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods struggle to produce monoclonal antibodies that specifically recognize dynamic epitopes, which are promising target molecules due to their complex sugar chain and peptide structures, as these epitopes are often degraded during antigen processing and have low affinity with enzymes, making it difficult to obtain antibodies that bind effectively.
A complex is developed that includes a neuraminic acid group or derivative, an antigenic site from glycoproteins or glycopeptides, and a carrier site, which binds to cells with neuraminidase 1 or 3, allowing for the presentation of glycopeptides as antigens without relying on MHC molecules, enabling the production of monoclonal antibodies that recognize both sugar chains and peptides.
This method allows for the efficient production of monoclonal antibodies that specifically bind to dynamic epitopes, improving cancer treatment by effectively presenting antigens and inducing antigen-specific B cells, thereby enhancing antibody production and cancer therapy.
Smart Images

Figure JP2024017786_28112024_PF_FP_ABST
Abstract
Description
Conjugate, pharmaceutical composition, vaccine and application thereof
[0001] The present invention relates to a conjugate, a pharmaceutical composition, a vaccine, a method for obtaining antigen-presenting cells, a method for producing antibodies, and a method for treating tumors and / or cancers.The present invention relates to providing a conjugate useful for producing antibodies against epitopes for which it has been difficult to produce antibodies so far.
[0002] The biggest and most serious challenge in developing therapeutic antibodies is the depletion of disease-specific antigens. Monoclonal antibodies are being actively developed around the world, and the current situation is that antibodies obtainable by conventional methods have been nearly exhausted. Therefore, in recent years, the development of various engineered antibody-related drugs, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen T cells, aimed at improving efficacy and safety, has been prioritized. Consequently, research into disease-specific and unidentified antigens (target molecules) that are expected to lead to the development of new antibody drugs has seen little progress.
[0003] In 2009, the inventors demonstrated for the first time at the molecular level that "antibodies exist that simultaneously recognize and bind to both the glycan and peptide domains of a glycopeptide molecule" (Nishimura, S.-I. et al., "An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library." J. Am. Chem. Soc. 2009, 131, 17102-17109). Furthermore, they demonstrated that "the binding specificity and affinity of such antibodies to cancer-specific antigenic determinants (epitopes) are strongly influenced by posttranslational glycosylation in this antigenic peptide domain" (Nishimura, S.-I. et al., "Convergent solid-phase synthesis of macromolecular MUC1 models truly mimicking serum glycoprotein biomarkers of interstitial lung diseases." J. Am. Chem. Soc. 2016, 138, 8392-8395).
[0004] These findings led to the proposal of a new principle, the "dynamic epitope theory," which can be generalized as a new molecular mechanism for the formation of protein antigen structures. Newly discovered "dynamic epitopes" in various diseases are a treasure trove of antigens that can become new target molecules, and are therefore expected to be a trump card in solving the problem of "antigen depletion."
[0005] However, it has become clear that obtaining antibodies that bind specifically and with high affinity to such promising target molecules, ``dynamic epitopes,'' is difficult and requires trial and error in immunization methods and multi-stage antibody screening (e.g., Non-Patent Document 3: Nishimura, S.-I. et al., A straightforward approach to antibodies recognizing cancer-specific glycopeptidic neoepitopes. Chem. Sci., 2020, 11, 4999-5006). This is because glycopeptides (dynamic epitopes) that are to be recognized by B cells as antigens (B cell-epitopes) by immunization are: ・taken up by dendritic cells or macrophages, which are antigen-presenting cells, and then the sugar chain region is easily degraded and removed by various glycosidases during processing in the lysosome before binding to MHC I / II (Major Histocompatibility Complex class I / II, mainly MHC II). Furthermore, ・the glycopeptide (dynamic epitope), which is the B cell-epitope, itself is bound to the antigen peptide (T cell-epitope) binding region of the MHC molecule (for example, Non-Patent Document 4: Germain, RN MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 1994, 75, 287-299; Non-Patent Document 5: Blum, JS, et al., Pathways of antigen processing. Annu. Rev. Immunol. 2013, 31, This is thought to be due to the low affinity of glycopeptides to glycopeptides (443-473). Therefore, there was an urgent need to establish a new methodology for obtaining monoclonal antibodies that simultaneously and specifically recognize both the glycans and peptides that make up the dynamic epitope, glycopeptides.
[0006] WO2017 / 131242
[0007] Nishimura, S.-I. et al., J. Am. Chem. Soc. 2009, 131, 17102-17109Nishimura, S.-I. et al., J. Am. Chem. Soc. 2016, 138, 8392-8395Nishimura, S.-I. et al., Chem. Sci., 2020, 11, 4999-5006Germain, RN Cell 1994, 75, 287-299Blum, JS, et al., Annu. Rev. Immunol. 2013, 31, 443-473
[0008] An objective of the present invention is to provide a complex for obtaining a monoclonal antibody that simultaneously and specifically recognizes both regions of a glycopeptide consisting of a sugar chain and a peptide as a single molecule.
[0009] Specifically, in order to solve the above-mentioned problems, the present invention provides the following aspects: [1] A complex represented by the following formula (1): (In formula (1), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic moiety selected from glycoproteins and glycopeptides, CP is a carrier moiety, and X 1 and X 2 are each independently a single bond or a linking group. 1 is a group represented by the following formula (2): (In formula (2), R 2 is a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms; R 3 is a hydrocarbon group having 1 to 12 carbon atoms, and * is a bonding site with the benzene ring in formula (1). [3] In formula (2), R 2 is a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms. 3is an alkyl group having 1 to 3 carbon atoms. [5] The conjugate according to any one of [1] to [4], wherein the carrier moiety is at least one selected from the group consisting of lipid nanoparticles, metal nanoparticles, polysaccharides, and carrier proteins. [6] The conjugate according to any one of [1] to [5], which is used to bind to cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3). [7] The conjugate according to any one of [1] to [6], which is used for antibody production. [8] A pharmaceutical composition comprising the conjugate according to any one of [1] to [7]. [9] The pharmaceutical composition according to [8], which is used for the prevention and / or treatment of tumors and / or cancers.
[10] A vaccine comprising the conjugate according to any one of [1] to [7].
[11] A method for obtaining antigen-presenting cells that present the antigenic site and carrier site in formula (1) on their cell surface, comprising contacting the conjugate according to any one of [1] to [7] with cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
[12] A method for producing an antibody, comprising producing an antibody using the antigen-presenting cell according to
[11] .
[13] A method for treating tumors and / or cancers, comprising administering the conjugate according to any one of [1] to [7] and administering an antibody that binds to the antigenic site in formula (1).
[14] Use of the conjugate according to any one of [1] to [7] for producing an agent for preventing and / or treating tumors and / or cancers.
[15] A conjugate represented by the following formula (11): (In formula (11), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic site selected from glycoproteins and glycopeptides, and X 1 and X 2 are each independently a single bond or a linking group. 1
[16] The complex according to
[15] , wherein (In formula (2), R 2 is a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms; R 3is a hydrocarbon group having 1 to 12 carbon atoms, and * is the bonding site to the benzene ring in formula (1).
[17] In formula (2), R 2 is a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms. 3 is an alkyl group having 1 to 3 carbon atoms.
[19] A pharmaceutical composition comprising the conjugate according to any one of
[15] to
[18] .
[20] A method for obtaining an antigen-presenting cell that presents the antigenic site and carrier site in formula (11) on its surface, the method comprising contacting the conjugate according to any one of
[15] to
[18] with a cell having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
[0010]
[101] : the following formula: [wherein R1 is neuraminic acid, the dynamic epitope is selected from the group consisting of a protein or peptide, a sugar chain, or a complex of a protein or peptide and a sugar chain, and the carrier protein is a protein that exerts an immunogenic effect when combined with the dynamic epitope];
[102] : The compound according to
[101] for producing an antibody against a dynamic epitope;
[103] : The compound according to
[101] or
[102] , which can irreversibly bind to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) to form a complex containing NEU1 or NEU3, the dynamic epitope, and the carrier protein;
[104] : The compound according to
[103] , wherein NEU1 or NEU3 exists as a membrane protein in the cell membrane;
[105] : The compound according to
[104] , wherein the dynamic epitope and carrier protein portion of the compound complexed with NEU1 or NEU3 in the cell membrane are presented extracellularly;
[106] : a compound of the following formula: A method for forming a complex comprising neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3), the dynamic epitope, and the carrier protein by irreversibly binding a compound having the formula: [wherein the dynamic epitope is selected from the group consisting of a protein or peptide, a sugar chain, or a complex of a protein or peptide and a sugar chain, and the carrier protein is a protein that exerts an immunogenic effect when combined with the dynamic epitope] to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3);
[107] : The method according to
[106] , in which a nucleophilic reaction occurs between F of the difluoromethylaryl group of the compound and a nucleophilic side chain such as a glutamic acid or aspartic acid residue in or near the enzymatic active center of NEU1 or NEU3;
[108] : The method according to
[106] or
[107] , in which NEU1 or NEU3 exists as a membrane protein in a cell membrane;
[109] : The method according to
[108] , wherein the dynamic epitope and carrier protein portion of the compound are presented extracellularly upon forming a complex with NEU1 or NEU3, which exists as a membrane protein in the cell membrane;
[110] : A compound having the following formula: A method for producing antibodies against a dynamic epitope, comprising irreversibly binding a compound having the formula: [wherein the dynamic epitope is selected from the group consisting of a protein or peptide, a sugar chain, or a complex of a protein or peptide and a sugar chain, and the carrier protein is a protein that exerts an immunogenic effect when combined with the dynamic epitope] to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) to form a complex containing NEU1 or NEU3, the dynamic epitope, and the carrier protein, and presenting the dynamic epitope and carrier protein in the complex to target cells.
[0011] According to the present invention, it is possible to provide a complex for obtaining a monoclonal antibody that simultaneously and specifically recognizes both regions of a glycopeptide consisting of a sugar chain and a peptide as a single molecule.
[0012] Figure 1 shows that the enzymatic activity of a scaffold protein present as a membrane protein in the cell membrane can be inhibited using a specific reaction mechanism using the compounds of the present invention, and that by irreversibly binding the compounds of the present invention to the scaffold protein, a complex containing a dynamic epitope (and a carrier protein) that binds to the scaffold protein and the compound of the present invention can be formed. Figure 2 shows that monoclonal antibody clones produced and screened using the method of the present invention bind only to glycopeptides and do not exhibit affinity for the backbone peptide. Figure 3 shows that monoclonal antibody clones produced using the method of the present invention strongly bind to the SARS-CoV-2 wild-type spike glycoprotein (S1 WT) and the Delta-type spike glycoprotein (S1 Delta) (Figures 3(A) and 3(B)), and that some subclones also strongly bind to the RBD of the recombinant spike glycoprotein of the Omicron strain (BA.2.75) (Figure 3(C)). Figure 3(C) shows that monoclonal antibody clones generated by the method of the present invention strongly bind to the SARS-CoV-2 wild-type spike glycoprotein (S1 WT) and the SARS-CoV-2 Delta-type spike glycoprotein (S1 Delta) (Figures 3(A) and 3(B)). Some subclones also strongly bind to the RBD of the recombinant spike glycoprotein from the Omicron strain (BA.2.75). Figure 4 shows that monoclonal antibody clones generated by the method of the present invention strongly bind to the SARS-CoV-2 wild-type spike glycoprotein (S1 WT) on the nM order. Figure 5 shows representative examples of screening results using antibodies obtained by conventional methods and the reactivity of these antibodies with the SARS-CoV-2 wild-type spike glycoprotein (S1). Figure 6 shows that the compounds of the present invention were used to immobilize a dynamic epitope on NEU1 present on the surface of cancer cells, demonstrating that antibodies specific to the dynamic epitope can be induced and internalized within cancer cells.Figure 7 shows a scheme for inducing anti-MUC1 antibodies against cancer cells by binding a dynamic epitope (target molecule) that serves as the binding target for anti-MUC1 antibodies to NEU1 sialidase present on the cell surface of cancer cells. Figure 8 shows that all monoclonal antibody clones produced and screened using the method of the present invention bind only to glycopeptides and show no affinity for backbone peptides. Figure 9 shows that all monoclonal antibody clones produced using the method of the present invention bind only to glycopeptides and show no affinity for backbone peptides. Figure 10 shows that monoclonal antibodies against fibronectin glycoproteins strongly bind to glycopeptides with Sialyl-Tn attached at two positions, Thr2155 and Thr2156, but do not bind to glycopeptides with other glycosylation modifications (Tn or T) or glycopeptides with Sialyl-Tn attached at three positions, Thr2152, Thr2155, and Thr2156. Figure 11 shows that monoclonal antibodies against fibronectin glycoproteins strongly bind to glycopeptides with Sialyl-Tn attached at two sites, Thr2155 and Thr2156, but do not bind to glycopeptides with other sugar chain modifications (Tn or T) or glycopeptides with Sialyl-Tn attached at three sites, Thr2152, Thr2155, and Thr2156.
[0013] The present invention will be described in detail below. The following description may be based on representative embodiments and specific examples, but the present invention is not limited to such embodiments. In this specification, the term "dynamic epitope" refers to a glycopeptide (glycoprotein) formed by linking a sugar chain to a peptide (protein), and refers to a glycopeptide (glycoprotein) that appears due to post-translational sugar chain modification, etc. (differences in the modified position and sugar chain structure).
[0014] In this specification, a compound in which a difluoromethylaryl skeleton is linked to a "dynamic epitope," as represented by formula (1) or formula (11) described below, is referred to as a "conjugate." Note that in this specification, a "conjugate" is sometimes referred to as a compound, and the term "conjugate" encompasses compounds. Also, in this specification, glycopeptides and glycoproteins are sometimes collectively referred to simply as "glycopeptides."
[0015] The present inventors conducted extensive research aimed at producing antibodies against glycopeptides (glycoproteins), which have been difficult to produce antibodies against until now. As a result, they demonstrated that they can provide a complex useful for establishing a new methodology for obtaining monoclonal antibodies that simultaneously and specifically recognize both the glycans and peptides that make up glycopeptides, which are dynamic epitopes. Furthermore, they demonstrated that this complex can be used to provide a method for efficiently presenting glycopeptides (glycoproteins) as antigens based on a novel mechanism that is independent of MHC binding. This novel mechanism, independent of MHC binding, allows the glycan region of glycopeptides (glycoproteins) to be effectively presented and recognized by B cells (inducing antigen-specific B cells) without degradation, dramatically improving the efficiency of producing antibodies that specifically bind to "dynamic epitopes," which are antigenic structures consisting of target glycans and peptides. Furthermore, it also enables efficient uptake of cancer therapeutic antibodies that bind to dynamic epitopes into cancer cells.
[0016] (Complex) A first embodiment of the present invention relates to a composite represented by the following formula (1).
[0017]
[0018] In formula (1), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic moiety selected from glycoproteins and glycopeptides, CP is a carrier moiety, and X 1 and X 2 are each independently a single bond or a linking group. 1 is a substituent, and is a neuraminic acid group or a neuraminic acid derivative group, while R 1is sometimes simply written as neuraminic acid or a neuraminic acid derivative. In such cases, neuraminic acid can be read as a group derived from neuraminic acid (i.e., a neuraminic acid group), and a neuraminic acid derivative can be read as a group derived from a neuraminic acid derivative (i.e., a neuraminic acid derivative group).
[0019] The complex represented by formula (1) has R linked to the difluoromethylaryl skeleton. 1 The difluoromethylaryl skeleton has an antigenic moiety selected from glycoproteins and glycopeptides as the DE linked to the difluoromethylaryl skeleton, and further has a carrier moiety (CP) linked to the DE.
[0020] In formula (1), DE represents an antigenic site selected from glycoproteins and glycopeptides. A glycoprotein is a protein having a sugar chain, and a glycopeptide is a peptide having a sugar chain. In this specification, a compound having 50 or more amino acids bound together is referred to as a protein, and a compound having fewer than 50 amino acids is referred to as a peptide. Furthermore, in this specification, a "sugar chain" refers to a compound formed by a chain of one or more sugar units (monosaccharides and / or their derivatives). When two or more sugar units are linked together, the sugar units are bonded to each other by dehydration condensation via a glycosidic bond. The sugar constituting the sugar chain may be a monosaccharide, or the sugar chain may be composed of one, two, three, four, five, six, seven, or eight sugars. In the present invention, the sugar chain of a glycoprotein or glycopeptide may be a sugar chain having one of the four O-glycan structures (Tn, Sialyl-Tn, T, Sialyl-T) known to be observed in cancer cells.
[0021] In formula (1), the number of sugar chains possessed by the DE is not particularly limited as long as the DE has one or more sugar chains. The upper limit of the number of sugar chains possessed by the DE is, for example, preferably 20 or less, more preferably 15 or less, and even more preferably 10 or less.
[0022] In formula (1), DE is preferably a glycopeptide. The glycopeptide is preferably composed of, for example, 5 to 40 amino acid residues, and more preferably 10 to 30 amino acid residues. In this case, the glycopeptide preferably has 1 to 5 sugar chains.
[0023] The glycoprotein or glycopeptide represented by DE is not particularly limited as long as it can serve as an antigenic site. Examples of glycoproteins or glycopeptides represented by DE include the various MUC1 glycopeptides disclosed in WO 2010 / 050528 and WO 2011 / 135869, and glycopeptides produced by the glycopeptide synthesis method disclosed in JP 2012-167018 A.
[0024] In formula (1), CP represents a carrier moiety. The carrier moiety enhances antigenicity when an antibody is produced using the complex of the present invention, and is a moiety that exerts immunogenicity together with the antigenic moiety DE described above. Note that the carrier moiety, in combination with the antigenic moiety (DE) described above, increases the overall molecular weight, thereby exerting the immunogenicity of the antigenic moiety (DE), and therefore it is preferable that the carrier moiety (CP) itself does not have antigenicity.
[0025] The carrier portion preferably has a predetermined particle size to enhance the antigenicity of the antigenic portion (DE). The average particle size of the carrier portion is preferably 1 nm or more, more preferably 3 nm or more, and even more preferably 5 nm or more. The average particle size of the carrier portion is preferably 500 nm or less, more preferably 300 nm or less, and even more preferably 100 nm or less.
[0026] The carrier moiety is not particularly limited as long as it functions to increase the molecular weight of the antigenic site (DE) and thereby exert the immunogenicity of the antigenic site (DE). For example, it is preferably at least one selected from the group consisting of lipid nanoparticles, metal nanoparticles, polysaccharides, and carrier proteins. Lipid nanoparticles are nanoparticles containing lipids as a main component, and examples thereof include nanoparticles composed of lipid membranes such as liposomes and exosomes. Metal nanoparticles include gold nanoparticles, silver nanoparticles, copper nanoparticles, platinum nanoparticles, quantum dots, etc. Polysaccharides include chitosan, chitin, dextrin, hyaluronic acid, pectin, etc. The average molecular weight of the polysaccharide is preferably 1,000 or more, more preferably 3,000 or more. The average molecular weight of the polysaccharide is preferably 5,000,000 or less, more preferably 1,000,000 or less.
[0027] Among these, the carrier moiety is preferably a carrier protein. Various proteins can be used as the carrier protein. Examples of the carrier protein include keyhole limpet hemocyanin (KLH), concholepas hemocyanin (CCH), bovine serum albumin (BSA), ovalbumin (OVA), granulocyte macrophage colony-stimulating factor (GM-CSF), bovine thyroglobulin (BTG), and chicken gamma globulin (Chicken Gamma Globulin). Examples of the carrier protein include polymeric substances such as PEG (globulin, CGG), as well as synthetic polypeptides. The average molecular weight of the carrier protein is preferably 5 kDa or more, more preferably 10 kDa or more, and even more preferably 15 kDa or more. The average molecular weight of the carrier protein is preferably 2000 kDa or less, more preferably 1000 kDa or less, and even more preferably 500 kDa or less.
[0028] In formula (1), the difluoromethylaryl skeleton and DE may be directly linked. In addition, a linking group may exist between the difluoromethylaryl skeleton and DE. That is, in formula (1), X 1 is a single bond or a linking group. 1 is a linking group, the linking group is preferably a linking group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms. More specifically, the linking group is preferably a divalent hydrocarbon group or a group formed by combining a divalent hydrocarbon group with one or more of -O-, -NR-, -C(=O)-, and -N=.
[0029] In formula (1), the DE and the carrier moiety (CP) may be directly linked. Alternatively, a linking group may exist between the DE and the carrier moiety (CP). That is, in formula (1), X 2 is a single bond or a linking group. 2 is a linking group, the linking group is preferably a linking group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms. More specifically, the linking group is preferably a divalent hydrocarbon group or a group formed by combining a divalent hydrocarbon group with one or more of -O-, -NR-, -C(=O)-, and -N=.
[0030] In formula (1), X 1 and X 2 are each independently a linking group, the linking group preferably has an amide bond. The molecular weight of the linking group is preferably 500 or less, more preferably 400 or less, and even more preferably 300 or less.
[0031] In formula (1), R 1 is a structure derived from a NEU1 sialidase inhibitor or a NEU3 sialidase inhibitor, and R 1 is a neuraminic acid group or a neuraminic acid derivative group. 1 is preferably a neuraminic acid derivative group. In this specification, an example of the neuraminic acid derivative group is a group represented by the following formula (2). That is, in formula (1), R1 is preferably a group represented by the following formula (2):
[0032]
[0033] In formula (2), R 2 and R 3 are not particularly limited as long as they are each independently a substituent that does not inhibit binding to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3). In this embodiment, taking into account the degree of binding affinity with neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3), R 2 and R 3 In this embodiment, R 2 is a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms; R 3 is preferably a hydrocarbon group having 1 to 12 carbon atoms, and * is preferably the bonding site to the benzene ring in formula (1).
[0034] In formula (2), R 2 R is preferably a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms, and more preferably a group containing at least one atom selected from the group consisting of carbon atoms and oxygen atoms and having 10 or less carbon atoms. 2 Examples of R include a hydroxy group, an alkyl group having 1 to 10 carbon atoms, an alkoxy group having 1 to 10 carbon atoms, and an alkylamide group having 1 to 10 carbon atoms. 2 is preferably a hydroxy group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms, more preferably a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms, and particularly preferably a hydroxy group.
[0035] In formula (2), R 3is preferably a hydrocarbon group having 1 to 12 carbon atoms, more preferably a hydrocarbon group having 1 to 10 carbon atoms, and even more preferably a hydrocarbon group having 1 to 6 carbon atoms. Examples of hydrocarbon groups include aliphatic hydrocarbon groups (e.g., alkyl groups, alkenyl groups, alkynyl groups, cycloalkyl groups) and aromatic hydrocarbon groups (e.g., phenyl groups, naphthyl groups). Among these, R 3 is preferably an alkyl group having 1 to 6 carbon atoms or a phenyl group, more preferably an alkyl group having 1 to 3 carbon atoms, and particularly preferably a methyl group.
[0036] Conventionally, when glycoproteins or glycopeptides are presented as antigens on the cell surface, after they are taken up by antigen-presenting cells such as dendritic cells or macrophages, the glycan regions of these glycoproteins or glycopeptides are easily degraded and removed by various glycosidases during lysosomal processing before binding to MHC I / II (Major Histocompatibility Complex class I / II, mainly MHC II). This makes it impossible to obtain monoclonal antibodies that simultaneously recognize both the glycans and peptides that make up the glycopeptide, a dynamic epitope. However, in the present invention, by forming a complex as shown in the structural formula above, we have succeeded in presenting the antigen on the cell surface in an MHC-independent manner that is not dependent on binding to MHC molecules. As a result, the glycans are presented as antigens without being degraded and removed, making it possible to obtain monoclonal antibodies that simultaneously recognize both the glycans and peptides that make up the glycopeptide, a dynamic epitope. For example, it is known that cancer cells evade the immune system by modifying cell surface proteins with sugar chains, and if antibodies against dynamic epitopes can be effectively produced, it is believed that new therapeutic tools can be provided for various diseases. Thus, by using the compound (conjugate) of the present invention, antibodies with high specificity against dynamic epitopes can be produced, and the obtained antibodies can be used in the diagnosis and treatment of diseases such as cancer.
[0037] In one aspect, the conjugate of the present invention may be a compound having the following formula:
[0038]
[0039] In the formula, R1 is neuraminic acid, the dynamic epitope is selected from the group consisting of a protein or peptide, a glycan, or a complex of a protein or peptide and a glycan, and the carrier protein is a protein that exerts an immunogenic effect when combined with the dynamic epitope.
[0040] This compound has a structure in which neuraminic acid is bound as R1 of the difluoromethylaryl skeleton, and a molecule in which a dynamic epitope and a carrier protein are bound in series is bound separately from R1.
[0041] The "dynamic epitope" contained in this compound refers to an epitope structure that is generated by post-translational modification of a protein (particularly glycosylation) and is not dependent solely on the peptide structure. Generally, such dynamic epitopes often have poor antigenicity, and it is known that it is difficult to produce antibodies against such dynamic epitopes. The dynamic epitope may be, for example, an epitope portion that is independent of the primary structure of a protein having a structure in which a glycochain is bound to a protein, such as a glycochain or a complex of a protein or peptide with a glycochain. However, in the present invention, the dynamic epitope is preferably a glycoprotein or glycopeptide.
[0042] Although these dynamic epitope moieties have a significantly low mutation frequency, conventional antibody production methods have generally been unable to produce suitable antibodies. However, the method of the present invention is believed to enable these to be new therapeutic targets that have not previously been targeted. For example, it is known that cancers, etc., can evade the body's immune system by modifying cell surface proteins with sugar chains. If antibodies against dynamic epitopes can be effectively produced, it is believed that new therapeutic tools can be provided for various diseases. For this reason, the compounds of the present invention are advantageous in that they can be used to produce antibodies against dynamic epitopes.
[0043] The "carrier protein" contained in this compound refers to a protein that has the effect of conferring immunogenicity when combined with a dynamic epitope. Examples of proteins that can be used as such carrier proteins include carrier proteins commonly known in the art, such as keyhole limpet hemocyanin (KLH), concholepas hemocyanin (CCH), bovine serum albumin (BSA), ovalbumin (OVA), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
[0044] A second embodiment of the present invention relates to a complex represented by the following formula (11):
[0045]
[0046] In formula (11), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic site selected from glycoproteins and glycopeptides, and X 1 and X 2 are each independently a single bond or a linking group. 1 is R in the above formula (1). 1 The same applies to the DE in formula (11) and the same applies to the preferred range. DE in formula (11) is the same as DE in formula (1) above and the same applies to the preferred range. However, while the N-terminus of DE in formula (1) above is bonded to another atom, the N-terminus of DE in formula (11) is not bonded to another atom. A blocking group or the like may be linked to the N-terminus of DE in formula (11).
[0047] In formula (11), R 1 is a neuraminic acid group (a group derived from neuraminic acid) or a neuraminic acid derivative group (a group derived from a neuraminic acid derivative). 1is preferably a neuraminic acid derivative group. An example of the neuraminic acid derivative group is a group represented by the above formula (2). That is, in formula (11), R 1 is preferably a group represented by the above formula (2). 2 and R 3 The preferred range of R 2 is preferably a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms, and is particularly preferably a hydroxy group. 3 is preferably an alkyl group having 1 to 6 carbon atoms, more preferably an alkyl group having 1 to 3 carbon atoms, and particularly preferably a methyl group.
[0048] (Antigen Presentation Method) The conjugate of the present invention is preferably used to bind to cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3). Another aspect of the present invention provides a method for obtaining antigen-presenting cells that present the antigenic site and carrier site of formula (1) on their cell surface, the method comprising contacting a conjugate represented by formula (1) with cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3). Another aspect of the present invention provides a method for antigen presentation, the method comprising contacting the above-described conjugate with cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
[0049]
[0050] In formula (1), R 1 is neuraminic acid or a neuraminic acid derivative, DE is an antigenic moiety selected from glycoproteins and glycopeptides, CP is a carrier moiety, and X 1 and X 2 are each independently a single bond or a linking group.
[0051] In the method for obtaining antigen-presenting cells, the complex represented by formula (1) is bound to a scaffolding protein (neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) present on the surface of the cell membrane, thereby making it possible to present the dynamic epitope and carrier site (carrier protein portion) in the complex of the present invention extracellularly (antigen presentation) on the surface of the cell membrane. As a result, it is possible to obtain cells presenting the antigen.
[0052] The conjugate of the present invention and the scaffold protein (neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3)) can be linked by a chemical reaction, an enzymatic reaction, or the like that occurs between the conjugate of the present invention and the scaffold protein.
[0053] In the method for obtaining antigen-presenting cells, it is preferable to select the R1 moiety of the difluoromethylaryl skeleton shown below depending on the type of protein used as a scaffold.
[0054]
[0055] For example, when neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) is used as a scaffold protein in the cell membrane, a neuraminic acid group or a neuraminic acid derivative group can be selected as the R1 moiety of the compound of the present invention, and a NEU1 / NEU3 complex can be formed between NEU1 or NEU3 and the compound of the present invention based on the enzymatic specificity of NEU1 or NEU3. In this way, NEU1 or NEU3 functions as a scaffold in the cell membrane, allowing the dynamic epitope and carrier site (carrier protein moiety) in the complex of the present invention to be presented extracellularly.
[0056] In the conjugates of the present invention, the neuraminic acid or neuraminic acid derivative moiety in the R1 moiety functions as the enzymatic active site of NEU1 or NEU3. A nucleophilic reaction occurs between F of the difluoromethylaryl group in the conjugate and a nucleophilic side chain, such as a glutamic acid or aspartic acid residue, located within or near the enzymatic active center of NEU1 or NEU3, allowing one of the F moieties of the difluoromethylaryl backbone to form an irreversible bond with NEU1 or NEU3. As a result, a NEU1 or NEU3-difluoromethylaryl backbone-dynamic epitope (DE)-carrier protein (CP)-linked structure is formed on the cell surface (herein, such a structure is also referred to as a "NEU1 / NEU3-complex"). The irreversible binding between NEU1 or NEU3 and the dynamic epitope (DE) allows the dynamic epitope derived from the conjugate of the present invention and the carrier protein to be presented on the cell surface for a long period of time.
[0057] Based on the above description, in another aspect, the present invention provides a method for forming a NEU1 / NEU3 complex comprising neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3), a dynamic epitope, and a carrier protein, by irreversibly binding a compound having the following formula to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3):
[0058]
[0059] In the formula, the dynamic epitope is selected from the group consisting of a protein or peptide, a sugar chain, or a complex of a protein or peptide and a sugar chain, and the carrier protein is a protein that exerts the effect of an immunogen when combined with the dynamic epitope.
[0060] Since NEU1 or NEU3 exists as a membrane protein in the cell membrane, the compound of the present invention bound to NEU1 or NEU3 is presented on the outside of the cell membrane. The bond between NEU1 or NEU3 and the compound of the present invention can be formed by a nucleophilic reaction between F of the difluoromethylaryl skeleton of the compound of the present invention and a nucleophilic side chain such as a glutamic acid or aspartic acid residue in or near the enzymatic active center of NEU1 or NEU3.
[0061] Specifically, the enzymatic activity of NEU1 and / or NEU3, which exist as membrane proteins in the cell membrane, is inhibited by a specific reaction mechanism using the compounds of the present invention, and the compounds of the present invention irreversibly bind to NEU1 and / or NEU3, thereby forming a NEU1 / NEU3 complex containing NEU1 and / or NEU3, a dynamic epitope (and a carrier protein) that binds to the compounds of the present invention. A specific example of this reaction (for NEU1) is shown in Figure 1.
[0062] In addition, another aspect of the present invention can provide a method for obtaining antigen-presenting cells that present the antigenic site and carrier site in formula (11) on the cell surface, which method comprises contacting a complex represented by formula (11) with a cell having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
[0063]
[0064] In formula (11), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic site selected from glycoproteins and glycopeptides, and X 1 and X 2 are each independently a single bond or a linking group. The complex represented by formula (11) is 1 It has a neuraminic acid group or a neuraminic acid derivative group as the amino acid, and a dynamic epitope (DE) linked to a difluoromethylaryl skeleton.
[0065] In the present invention, the neuraminic acid or neuraminic acid derivative portion of the conjugate represented by formula (11) functions as the enzymatic active site of neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) present on the cell membrane surface. A nucleophilic reaction occurs between F of the difluoromethylaryl group in the conjugate and a nucleophilic side chain, such as a glutamic acid or aspartic acid residue, present in or near the enzymatic active center of NEU1 or NEU3, resulting in an irreversible bond between one of the F groups of the difluoromethylaryl skeleton and NEU1 or NEU3. As a result, an antigenic site (DE) selected from glycoproteins and glycopeptides represented by formula (11) is linked to the cell surface. This allows cells to present a dynamic epitope (antigen presentation) on the cell membrane surface.
[0066] In the method for obtaining antigen-presenting cells, it is preferable to select the R1 moiety of the difluoromethylaryl skeleton shown below depending on the type of protein used as a scaffold.
[0067]
[0068] For example, when neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) is used as a scaffold protein in the cell membrane, a neuraminic acid group or a neuraminic acid derivative group can be selected as the R1 moiety of the compound of the present invention, and a NEU1 / NEU3 complex can be formed between NEU1 or NEU3 and the compound of the present invention based on the enzymatic specificity of NEU1 or NEU3. In this way, NEU1 or NEU3 functions as a scaffold in the cell membrane, allowing the dynamic epitope and carrier site (carrier protein moiety) in the complex of the present invention to be presented extracellularly.
[0069] In the conjugates of the present invention, the neuraminic acid or neuraminic acid derivative moiety in the R1 moiety functions as the enzymatic active site of NEU1 or NEU3. A nucleophilic reaction occurs between F of the difluoromethylaryl group in the conjugate and a nucleophilic side chain, such as a glutamic acid or aspartic acid residue, located within or near the enzymatic active center of NEU1 or NEU3, allowing one of the F moieties of the difluoromethylaryl backbone to form an irreversible bond with NEU1 or NEU3. As a result, a NEU1 or NEU3-difluoromethylaryl backbone-dynamic epitope (DE)-linked structure is formed on the cell surface (herein, such a structure is also referred to as a "NEU1 / NEU3-conjugate"). The irreversible binding between NEU1 or NEU3 and the dynamic epitope (DE) allows the dynamic epitope derived from the conjugate of the present invention and a carrier protein to be presented on the cell surface for a long period of time.
[0070] By utilizing this mechanism, the compounds of the present invention can be bound to target cells in which NEU1 and NEU3 are present on the cell membrane surface, thereby presenting the dynamic epitopes and carrier proteins bound to the compounds of the present invention to the target cells, which can be selected from immune cells, cancer cells, and the like.
[0071] Immune system cells that can be used as target cells include activated macrophages, dendritic cells, T cells, etc. When a dynamic epitope is presented to immune system cells using the compound of the present invention, antibodies against the dynamic epitope can be produced.
[0072] Cancer cells that can be used as target cells may be any type of cancer cell, including lung cancer, hepatocellular carcinoma, and colon cancer. By binding the compounds of the present invention to NEU1 or NEU3 on cancer cells, existing antibodies that bind to dynamic epitopes can be delivered to the cancer cells. Such existing antibodies that bind to dynamic epitopes may be antibodies that target cancer cells or antibodies that form antibody-drug conjugates (ADCs). The dynamic epitope can be appropriately selected depending on the type of antibody used.
[0073] (Method for producing antibodies) The conjugate of the present invention is preferably used for producing antibodies. In another aspect, the present invention can provide a method for producing antibodies, comprising producing an antibody using an antigen-presenting cell that presents the antigenic site and the carrier site of formula (1) on its cell surface.
[0074]
[0075] In formula (1), R 1 is neuraminic acid or a neuraminic acid derivative, DE is an antigenic moiety selected from glycoproteins and glycopeptides, CP is a carrier moiety, and X 1 and X 2 are each independently a single bond or a linking group.
[0076] In the antibody production method, antigen-presenting cells prepared by the above-described method are presented to immune system cells such as activated macrophages, dendritic cells, and T cells. Because the complex of the present invention has the structure shown in formula (1) above, it is possible to present antigens on the cell surface in an MHC-independent manner that does not depend on binding to MHC molecules. Therefore, the antigens presented to immune system cells have glycans, and monoclonal antibodies that simultaneously recognize both the glycans and peptides that constitute glycopeptides can be obtained. Furthermore, the present invention also makes it possible to obtain monoclonal antibodies that recognize only the glycans in the antigen-presented glycoproteins and glycopeptides.
[0077] Based on the above description, in another aspect, the present invention provides a method for producing antibodies against a dynamic epitope by irreversibly binding a complex having the following formula to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) to form a complex containing NEU1 or NEU3, a dynamic epitope, and a carrier protein, and presenting the dynamic epitope and carrier protein in the complex to immune system cells.
[0078]
[0079] In the formula, the dynamic epitope is selected from the group consisting of a protein or peptide, a sugar chain, or a complex of a protein or peptide and a sugar chain, and the carrier protein is a protein that exerts the effect of an immunogen when combined with the dynamic epitope.
[0080] In the present invention, immune system cells such as activated macrophages, dendritic cells, and T cells can be used as immune system cells to which dynamic epitopes and carrier proteins are presented by the compounds of the present invention.
[0081] (Use) The conjugates represented by formulas (1) and (11) are preferably used to bind to cells having a scaffold protein, as described below. Preferred examples of the scaffold protein include neuraminidase 1 (NEU1) and neuraminidase 3 (NEU3). That is, the conjugates of the present invention are preferably used to bind to cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
[0082] Among these, the conjugate represented by formula (1) is preferably used for antibody production. As described below, binding of the conjugate to cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) as scaffold proteins on the cell membrane surface results in the production of antigen-presenting cells that present antigenic and carrier moieties on the cell surface. The antigen-presenting cells then present antigens to activated immune cells such as macrophages, dendritic cells, and T cells, enabling the production of antibodies specific to glycan-containing antigens (dynamic epitopes).
[0083] Furthermore, the conjugates represented by formulas (1) and (11) are also useful for pharmaceutical applications in treating tumors and / or cancers. It is known that neuraminidase 1 (NEU1) and / or neuraminidase 3 (NEU3) are highly expressed on the surface of tumor and / or cancer cells (target cells). Therefore, for example, an antigenic site for which an antibody is already known can be introduced into the conjugate of the present invention and then contacted with target cells highly expressing neuraminidase 1 (NEU1) and / or neuraminidase 3 (NEU3), thereby presenting the antigenic site and carrier site on the surface of the target cells. Then, by acting the antibody on the antigen-presenting cells, the antibody binds to the target cells or enters the cells, thereby repelling the target cells. The antibody may also form an antibody-drug conjugate (ADC).
[0084] (Pharmaceutical Composition / Vaccine) In another aspect, the present invention can also provide a pharmaceutical composition containing the above-mentioned conjugate. The conjugate of the present invention can be administered alone as it is, or may be administered after being mixed with pharmaceutically acceptable formulation components. The pharmaceutical composition of the present invention is used for animals and humans.
[0085] An example of the pharmaceutical composition is a vaccine. That is, in another aspect, the present invention can provide a vaccine containing the above-described complex.
[0086] The route of administration of the pharmaceutical composition is preferably the most effective for the treatment, and examples thereof include oral or parenteral routes such as nasal, rectal, buccal, subcutaneous, intramuscular, and intravenous. Dosage forms include capsules, tablets, granules, powders, syrups, emulsions, suppositories, and injections. Liquid preparations suitable for oral administration, such as emulsions and syrups, can be prepared using water, sugars such as sucrose, sorbitol, and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil, and soybean oil, preservatives such as p-hydroxybenzoic acid esters, and flavors such as strawberry flavor and peppermint. Furthermore, capsules, tablets, powders, granules, etc. can be produced using excipients such as lactose, glucose, sucrose, mannitol, etc., disintegrants such as starch, sodium alginate, etc., lubricants such as magnesium stearate, talc, etc., binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin, etc., surfactants such as fatty acid esters, plasticizers such as glycerin, etc.
[0087] Preparations suitable for parenteral administration preferably consist of a sterile aqueous preparation containing an active compound that is isotonic with the recipient's blood. For example, in the case of an injection, a solution for injection is prepared using a carrier such as a saline solution, a glucose solution, or a mixture of saline and glucose solution. In addition, parenteral preparations may also contain one or more auxiliary ingredients selected from glycols, oils, flavors, preservatives (including antioxidants), excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc., as exemplified for oral preparations.
[0088] The pharmaceutical composition of the present invention may be used for the prevention and / or treatment of tumors and / or cancers. For example, administration of the pharmaceutical composition of the present invention can produce antibodies that prevent and / or treat tumors and / or cancers.
[0089] The pharmaceutical composition of the present invention may also be a combination formulation of a first agent containing the above-described conjugate and a second agent containing an antibody that binds to the antigenic site of the above-described conjugate. For example, an antibody having a known antigenic site can be introduced into the conjugate of the present invention, and then contacted with target cells highly expressing neuraminidase 1 (NEU1) and / or neuraminidase 3 (NEU3), thereby presenting the antigenic site and carrier site on the surface of the target cells. Then, by acting the antibody on the antigen-presenting cells, the antibody binds to the target cells and enters the cells, thereby treating tumors and / or cancers.
[0090] The effective dose and frequency of administration of the pharmaceutical composition vary depending on the structure of the complex, the administration form, the age and body weight of the patient, the nature or severity of the symptoms to be treated, etc., and are determined by comprehensively considering these factors. Furthermore, the higher the binding affinity to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3), the more likely it is that a smaller dose will produce a medicinal effect.
[0091] (Method for treating tumors and / or cancer) In another aspect, the present invention can provide a method for treating tumors and / or cancer, comprising administering a conjugate and administering an antibody that binds to the antigenic site in formula (1) or formula (11). However, the treatment method of the present invention may exclude methods for treating humans. Another aspect of the present invention relates to use of the above-mentioned conjugate for producing an agent for preventing and / or treating tumors and / or cancer.
[0092] It is known that neuraminidase 1 (NEU1) and / or neuraminidase 3 (NEU3) are highly expressed on the surface of tumor and / or cancer cells (target cells). Therefore, for example, an antigenic site for which an antibody is already known can be introduced into the conjugate of the present invention, and the conjugate can be contacted with target cells highly expressing neuraminidase 1 (NEU1) and / or neuraminidase 3 (NEU3), thereby presenting the antigenic site on the surface of the target cells. Then, by acting the antibody on the cells presenting the antigen, the antibody binds to the target cells and enters the cells, thereby treating tumors and / or cancers. The antibody may also be an antibody that has formed an antibody-drug conjugate (ADC).
[0093] In another aspect, the present invention can also provide a method for inducing antibodies against dynamic epitopes into cancer cells by irreversibly binding a compound of the present invention to neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) present on the cell membrane of a cancer cell to form a complex containing NEU1 or NEU3 and a dynamic epitope, and then binding an existing antibody that specifically binds to the dynamic epitope in the complex.
[0094] By utilizing the compounds of the present invention, even in cases where existing antibodies have low specificity for cancer cells and are unable to treat cancer cells efficiently, or where no therapeutic antibody specific to a particular cancer cell type exists, it is possible to efficiently induce therapeutic antibodies against cancer cells or to efficiently induce therapeutic drugs bound to antibodies to cancer cells.
[0095] The present invention will be specifically illustrated by the following examples, which are not intended to limit the present invention in any way.
[0096] Example 1: Synthesis of terminal compound (1-1) Compound 8 (NEU1 sialidase inhibitor derivative 8) was synthesized according to the reaction scheme shown below.
[0097]
[0098] Compound 8, which reacts specifically and readily with compounds containing ketone or aldehyde groups in aqueous solution under mild, weakly acidic conditions, can be synthesized by methods previously described (e.g., WO2017 / 131242; Nishimura, S.-I. et al., Characterization of Vibrio cholerae neuraminidase by a novel mechanism-based fluorescent labeling reagent. Biochemistry 2005, 44, 11669-11675). Specifically, it was synthesized by condensation of the above compound 6 with Boc-aminooxy acetic acid, followed by deprotection of the acetyl group and hydrolysis of the methyl ester.
[0099] 1 H NMR (600 MHz, D2O) δ ppm 7.66 (s, 1H), 7.47 (d, 1H), 7.32 (d, 1H), 7.00 (t, 1H), 4.42 (s, 2H), 3.90 (t, 1H), 3.86 (t, 1H), 3.75 (m, MALDI-TOFMS: m / z calcd for C 25 H 35 F2N3O 13 [M+Na] + 646.203, found 646.437.
[0100] (1-2) Compound 9 (NEU1 sialidase inhibitor derivative 9) was synthesized according to the reaction scheme shown below.
[0101]
[0102] Compound 9, which is used as a cap at the N-terminus of peptides and glycopeptides when presented as antigens, was obtained by the reaction of compound 6 with glutaric anhydride in the final step of solid-phase synthesis.
[0103] 1 H NMR (600 MHz, CDCl3) δ ppm 7.93 (s, 1 H, CONH), 7.83 (s, 1 H, Ar), 7.56 (d, J=9.1 Hz, 1 H, Ar), 7.24 (d, J=8.7 Hz, 1 H, Ar), 6.90 (t, J=55.2 Hz, 1 H, CHF2), 5.46 (d, J=10.2 Hz, 1 H, NHAc), 5.38 (m, 2 H, H-7, H-8), 4.98 (td, J=11.1, 4.2 Hz, 1 H, H-4), 4.44 (d, J=10.6 Hz, 1 H, H-6), 4.31 (dd, J=12.4, 1.8 Hz, 1 H, H-9), 4.13 (m, 2 H, H-5, H-9), 3.67 (s, 3 H, COOMe), 2.75 (dd, J=12,8, 4.5 Hz, 1 H, H-3 eq ), 2.50 (m, 4 H, 2×linker CH2), 2.24 (t, J=12.5 Hz, 1 H, H-3 ax ), 2.16 (2×s, 6 H, 2×Ac), 2.07 (m, 8 H, 2×Ac, linker CH2), 1.94 (s, 3 H, Ac).
[0104] 13 C NMR (150 MHz, CDCl3) δ ppm 123.02, 120.38, 117.43 (Ar), 73.24 (C-6), 68.73 (C-8), 68.31 (C-4), 66.94 (C-7), 61.80 (C-9), 52.99 (COOMe), 49.21 (C-5), 37.69 (C-3), 35.90 (linker CH2), 32.54 (linker CH2), 22.95, 20.96, 20.79 (Ac), 20.01 (linker CH2).
[0105] MALDI-TOFMS: m / z calcd for C 32 H 40 F2N2O 16 [M+Na] + 769.224, found 769.207.
[0106] Example 2: Synthesis of dynamic epitopes (antigenic sites) Antigenic glycopeptides of the SARS-CoV-2 spike glycoprotein were synthesized as dynamic epitopes (antigenic sites).
[0107] (2-1) Glycopeptide precursor 10 having a 5-oxohexanoic acid residue was synthesized according to the reaction scheme shown below. Glycopeptide precursor 10: 5-oxohexanoic acid- 334 Gln-Val-Ser-Pro-Phe-Gly-Glu-Val-Phe-Asn(Fucα1,6GlcNAcβ1)-Ala-Thr-Arg-Phe-Ala-Ser-Val 350 -Cys-NH2 (SEQ ID NO: 1)
[0108] The precursor 10 of the glycopeptide antigen (compound 11, described below) in the RBD of the SARS-CoV-2 spike glycoprotein was synthesized by Fmoc solid-phase peptide synthesis. The synthesis proceeded sequentially using Rink Amide-ChemMatrix resin (0.42 mmol / g, 100 mg, 42 μmol) in a DMF solution containing Fmoc amino acid derivatives (168 μmol), HBTU (168 μmol), and HOBt (168 μmol) under microwave irradiation at 50°C, with each step lasting 10 min. Unreacted amino acids were acetylated by treatment with acetic anhydride / DIEA / DMF (v:v:v = 0.5:1:8.5) for 30 s at room temperature. The Fmoc group was deprotected by treatment with 20% piperidine / DMF for 3 min under microwave irradiation at 50°C.
[0109] The target peptide was synthesized by repeating these three steps: (A) elongation of various Fmoc amino acids, (B) acetylation of unreacted amino groups, and (C) de-Fmocation. 343 At position (I), instead of the usual Fmoc amino acid derivative, an Fmoc sugar amino acid derivative bound to a disaccharide consisting of fucose and N-acetylglucosamine was separately prepared by Enyu Pharma Co., Ltd., and used to carry out the synthetic reaction.
[0110] After condensation of all amino acids and sugar amino acids, 5-oxohexanoic acid was condensed to the N-terminal amino group under the same conditions as for Fmoc amino acid elongation. The reaction mixture was then mixed with trifluoroacetic acid:water:phenol:thioanisole:1-dodecanethiol (v:v:v:v:v = 82.5:5:5:5:2.5) and shaken at room temperature for 2 hours to cleave the desired synthetic intermediate from the solid support and simultaneously deprotect the side chains.
[0111] The reaction solution was filtered, tert-butylmethyl ether was added, and the mixture was centrifuged (5000 G, 4°C, 10 min). The supernatant was discarded, and the precipitate was dissolved in 50% aqueous acetonitrile and lyophilized to obtain the crude glycopeptide precursor 10. This lyophilized product was dissolved in methanol, adjusted to pH 12.5 with 1 N sodium hydroxide solution, and shaken at room temperature for 1 hour to deprotect the acetyl groups in the glycan region. The solution was then neutralized with 30% aqueous acetic acid, and the solvent was removed under reduced pressure. The product was then purified by reversed-phase high-performance liquid chromatography to obtain the desired glycopeptide precursor 10.
[0112]
[0113] MALDI-TOFMS: m / z calculation for C 108 H 163 N 24 O 37 S [M+H]+ 2420.133, found 2420.168.
[0114] (2-2) Next, glycopeptide antigen 11 was synthesized as follows. The glycopeptide precursor 10 (1 mM) was reacted with an oxazolinyl glycan derivative (5 mM) prepared according to a known method (Shoda, S.-i. et al., J. Org. Chem. 2009, 74, 2210-2212) and Endo-F3 (100 U / mL) in 100 mM HEPES (pH 7.0) at 37°C for 4 hours. The reaction mixture was purified by reversed-phase high-performance liquid chromatography to obtain glycopeptide antigen 11 as a lyophilized powder (yield: 26.2%).
[0115]
[0116] MALDI-TOFMS: m / z calculation for C 184 H 284 N 29 O 93 S [MH]- 4419.8181, found 4418.978
[0117] The following non-glycosylated peptide (SEQ ID NO: 2) used for antibody screening was also synthesized in the same manner.
[0118]
[0119] MALDI-TOF MS: m / z calculation for C 94 H 140 N 23 O 28 S [M+H]+ 2070.991 ,found 2070.843.
[0120] Example 3: Conjugation of dynamic peptide (antigen) with terminal compound Conjugate 12 was synthesized by conjugating compound 8 (NEU1 sialidase inhibitor derivative 8) synthesized in Example 1 with glycopeptide antigen 11, a dynamic peptide synthesized in Example 2.
[0121] Compound 8 (NEU1 sialidase inhibitor derivative 8) (50 mM) synthesized in Example 1 was allowed to stand in 1 N aqueous hydrochloric acid at 40°C for 1 hour. The solution was then neutralized by adding aqueous ammonium bicarbonate. The sialidase inhibitor, deprotected by HPLC to expose the aminooxy group, was purified and lyophilized, and then immediately coupled with glycopeptide antigen 11 synthesized in Example 2.
[0122] The synthesis reaction was carried out by dissolving the glycopeptide (final concentration 1 mM) and the deprotected sialidase inhibitor (final concentration 20 mM) in 100 mM acetate buffer (pH 4), followed by centrifugal concentration for 16 hours. After purification by HPLC, conjugate 12 was obtained.
[0123]
[0124] MALDI-TOF MS: m / z calculation for C 204 H 309 F2N 32 O 103 S [MH]- 4924.969, found 4924.930
[0125] Example 4: Antibody Production Using Conjugate Conjugate 12 prepared in Example 3 was conjugated with KLH (carrier protein) using the maleimidobenzoyloxysuccinimide (MBS) method to obtain a conjugate for antibody production. The resulting conjugate for antibody production was administered subcutaneously at the base of the tail of three mice (B6D2F1 / Slc) at approximately 0.1 mg to elicit an immune response. A booster immunization was administered 17 days later using the same method, and blood was collected four days later. Iliac lymph nodes were then collected. Lymphocytes collected from the collected iliac lymph nodes were fused with myeloma cells SP2 and cultured in HAT selection medium to select antibody-producing cells.
[0126] Next, the culture supernatant of the obtained hybridoma was plated on an ELISA plate, and positive wells were selected based on binding to a bovine serum albumin (BSA)-glycopeptide antigen complex (BSA-MBS-glycopeptide (19-1) conjugate) and to a BSA-peptide antigen complex (a complex of BSA and the non-glycosylated peptide prepared in Example 2) (BSA-MBS-non-glycosylated peptide (19-1) conjugate). Screening was performed by binding reactions with the dynamic epitope glycopeptide and the control non-glycosylated peptide.
[0127] Cloning of the fused cells was performed using limiting dilution and other methods. Figure 2 shows the binding specificity of the culture supernatants of six single clones (subclones A-1 to A-6 and subclones B-1 to B-6) obtained from each of the two clone lineages, clone A and clone B, to glycopeptides (dynamic epitopes). These results demonstrate that the antibodies obtained from the culture supernatants of these clones bind only to glycopeptides and do not exhibit affinity for non-glycosylated peptides.
[0128] Example 5: Evaluation of the binding specificity of monoclonal antibodies to the SARS-CoV-2 spike glycoprotein The binding specificity of the monoclonal antibodies against the SARS-CoV-2 spike glycoprotein prepared in Example 4 to the SARS-CoV-2 spike glycoprotein was examined.
[0129] 100 μL of SARS-CoV-2 S1 protein dissolved in PBS at a concentration of 1 μg / mL was added to the wells of a nonspecific binding ELISA plate (Sumitomo Bakelite Co., Ltd.) and incubated overnight at 4°C. After discarding the solution and washing the wells with PBS, 200 μL of 1% BSA-containing PBS was added to the wells and incubated at room temperature for 2 hours to block the surface. After discarding the solution and washing the wells, each culture supernatant was diluted 10-fold with ELISA buffer (25 mM Tris, 150 mM NaCl, 0.05% Tween-20, 0.1% BSA, pH 7.5), and 100 μL of each was added to the plate and incubated at room temperature for 2 hours. The wells were then washed in the same manner, and 100 μL of anti-mouse IgG antibody AP conjugate (Promega) diluted 1 / 2500 in ELISA buffer was added and incubated at room temperature for 1 hour.
[0130] The solution was discarded, and the wells were washed with PBS to completely remove the secondary antibody. After that, 4-nitrophenol phosphate solution was added and incubated at room temperature for 2 hours. The absorbance at 405 nm was measured using a plate reader.
[0131] The results are shown in Figure 3. Both antibodies obtained from the culture supernatants of clones A and B were shown to strongly bind to the spike glycoprotein of the SARS-CoV-2 wild-type strain (S1 WT) and the spike glycoprotein of the Delta strain (S1 Delta) (Figures 3(A) and 3(B)). Furthermore, subclones A-4 and A-2 were found to strongly bind to the RBD of the recombinant spike glycoprotein of the Omicron strain (BA.2.75), to which sotrovimab cannot bind (Figure 3(C)).
[0132] Example 6: Evaluation of the binding affinity of monoclonal antibodies to the SARS-CoV-2 spike glycoprotein The binding affinity of the monoclonal antibodies against the SARS-CoV-2 spike glycoprotein prepared in Example 4 to the SARS-CoV-2 spike glycoprotein was examined.
[0133] Recombinant SARS-CoV2 S1-mFc (Sino Biological) was immobilized on an SPR sensor chip CM5 by the amine coupling method. The dissociation constants of monoclonal antibodies subclone A-2 and subclone B-3, purified with a Spin column-based Antibody Purification Kit (Protein G) (Thermo Fisher Scientific), and SARS-CoV2 S1-mFc were calculated using a Biacore2000.
[0134] The results are shown in Figure 4. The dissociation constants were Kd = 7.4 nM for subclone A-2 and Kd = 17 nM for subclone B-3 (Figure 4). These results demonstrate that the monoclonal antibody clones generated using the conjugates of the present invention strongly bind to the spike glycoprotein (S1 WT) of the wild-type SARS-CoV-2 strain on the order of nanomolar.
[0135] Example 7: Verification of the Significance and Necessity of Conjugating Irreversible NEU1 Sialidase Inhibitors In the present invention, a conjugate having an antigenic site is covalently bound to NEU1 sialidase on immune cells or cancer cells, thereby presenting an antigen on the cell surface and producing an antibody. While various antibodies obtained using conventional techniques have occasionally shown superiority for glycopeptides, most have been reported to also exhibit strong binding affinity for peptides lacking glycans (e.g., Corzana, F. et al., Chem. Soc. Rev. 2017, 46, 7154-7175). In other words, conventional techniques have made it difficult to produce antibodies highly specific for glycopeptides containing glycans.
[0136] The purpose of this example was to conduct a comparative experiment to demonstrate the significance and necessity of conjugating an antigenic site with a NEU1 sialidase irreversible inhibitor. A glycopeptide antigen-KLH conjugate was prepared by a conventional method without conjugating the NEU1 sialidase irreversible inhibitor, and an antibody was isolated.
[0137] A glycopeptide (SEQ ID NO: 3) containing two glycosylation sites, Thr323 and Ser325, of the SARS-CoV-2 spike glycoprotein and bearing a terminal 5-oxohexanoic acid residue and an unglycosylated peptide (SEQ ID NO: 4) were synthesized using Fmoc-Thr[Ac4Galβ(1→3)Ac2GalNAcα1→]-OH and Fmoc-Ser[Ac4Galβ(1→3)Ac2GalNAcα1→]-OH according to the solid-phase synthesis protocol of compound 10.
[0138]
[0139] MALDI-TOF / MS: m / z calculation for C 127 H 203 N 30 O 48 S [M+H]+ 2948.404, found 2948.516
[0140]
[0141] MALDI-TOF / MS: m / z C 99 H 156 N 28 O 28 S [M+H]+ 2218.140, found 2218.112
[0142] The glycopeptide antigens and glycosylated peptide antigens not conjugated with the NEU1 sialidase irreversible inhibitor were conjugated to KLH using the maleimidobenzoyloxysuccinimide (MBS) method and administered subcutaneously at the base of the tail of three mice (B6D2F1 / Slc) at approximately 0.1 mg to elicit an immune response. A booster immunization was administered 17 days later using the same method, and blood was collected four days later, after which iliac lymph nodes were harvested. Lymphocytes collected from the harvested iliac lymph nodes were fused with myeloma cells SP2 and cultured in HAT selection medium to select antibody-producing cells.
[0143] Next, the culture supernatants of the obtained hybridomas were plated on ELISA plates, and positive wells were selected by binding to the BSA-glycopeptide antigen complex and the BSA-peptide antigen complex, and then screened by binding to the dynamic epitope glycopeptide and the control non-glycosylated peptide.
[0144] Representative examples of screening results using antibodies generated by conventional methods using glycopeptide antigen-KLH complexes and their reactivity with the SARS-CoV-2 wild-type spike glycoprotein (S1) are shown in Figure 5. Antibodies generated by conventional methods were unable to recognize the glycans of the antigen (Figure 5A), nor did they react with the wild-type spike protein (S1 WT) (Figure 5B; clone names are omitted in the figure).
[0145] Glycopeptide antigen-KLH complexes not conjugated with a NEU1 sialidase irreversible inhibitor are not presented extracellularly, but are instead taken up by dendritic cells and other cells. After being degraded into antigenic peptides, they are presented on the cell surface by major histocompatibility complex (MHC) class II molecules. Therefore, glycopeptide antigen-KLH complexes not conjugated with a NEU1 sialidase irreversible inhibitor are not presented as antigens in the form of glycans, and as a result, antibodies that specifically bind to dynamic epitopes with glycans are not produced (Figure 5). In contrast, in the present invention, by using a NEU1 sialidase irreversible inhibitor-glycopeptide antigen-KLH complex conjugated with a NEU1 sialidase irreversible inhibitor, the glycopeptide antigen is presented extracellularly without passing through the pathway of antigenic peptide presentation by MHC molecules (MHC-independent antigen presentation). This allows the glycopeptide to be presented extracellularly without the glycans and other components being degraded, enabling the production of antibodies that specifically bind to dynamic epitopes with glycans.
[0146] Example 8: Antigen (target molecule) presentation on the surface of cancer cells. Experiments were conducted to investigate whether a dynamic epitope (target molecule), which is the binding target of an anti-MUC1 antibody, could be bound to NEU1 sialidase present on the surface of cancer cells, thereby inducing anti-MUC1 antibodies against cancer cells. The scheme for inducing antibodies in this example is shown in Figure 6.
[0147] (8-1) Conjugation of Compound 8 with a Dynamic Epitope of an Anti-MUC1 Antibody (Synthesis of Compound 13) Compound 8 (50 mM) synthesized in Example 1 was incubated in 1 N aqueous hydrochloric acid at 40°C for 1 hour. Subsequently, aqueous ammonium bicarbonate was added to neutralize the solution. Compound 8, which had been deprotected by HPLC to expose the aminooxy group, was purified and lyophilized. Immediately after lyophilization, MUC1-Tn glycopeptide (SEQ ID NO: 5) (2 mg, final concentration 1 mM) and the deprotected compound 8 (final concentration 20 mM) were dissolved in 100 mM acetate buffer (pH 4). The reaction proceeded for 16 hours with centrifugation. The resulting solution was then purified by HPLC to yield 0.37 mg of conjugate 13.
[0148]
[0149] MALDI-TOF MS: m / z calculation for C 108 H 168 F2N 27 O 43 [M+H+]+ 2569.176, found 2569.137
[0150] (8-2) Uptake of anti-MUC1 antibodies into lung cancer cells by binding to the displayed dynamic epitope. A549 cells, which have been reported to be insensitive to the anti-MUC1 antibody SN-131, were seeded on a glass plate for microscopy (20,000 cells / well / 200 μL D-MEM medium containing 10% FBS) and cultured at 37°C for 24 hours under 5% CO2 conditions to allow the cells to adhere to the plate. Subsequently, (1) 20 μM complex 13 (synthesized in (8-1)) and (2) 20 μM complex 13 (synthesized in (8-1)) plus 1 mM DANA (2,3-didehydro-2-deoxy-N-acetylneuraminic acid, IC 50 After incubation at 37°C for 2 hours under 5% CO2, the medium was removed and the cells were washed three times with medium.
[0151] Hoechst 33342 (2.5 μg / mL), Alexa488-labeled SN-131 (2 μg / mL, WO2011 / 135869), and Opti-MEM medium were then added, and the cells were incubated for another hour. After washing twice with Opti-MEM, the cells were observed under a fluorescence microscope (BIOREV BZ-9000, Keyence), and images acquired with a BZ-II analyzer were analyzed.
[0152] The results are shown in Figure 7. In this figure, after reaction with complex 13, the anti-MUC1 antibody SN-131 (green) added as shown in (1) was taken up into A549 cells (Figure 7(1)), but this phenomenon was not observed in the presence of high concentrations of DANA, a small molecule reversible inhibitor of NEU1, as shown in (2) (Figure 7(2)).
[0153] These results indicated that the SN-131-MUC1-Tn-NEU1 complex was endocytosed into A549 cells through specific binding between the anti-MUC1 antibody SN-131 and MUC1-Tn (a dynamic epitope of SN-131) covalently displayed on NEU1 on the surface of cancer cell membranes via an irreversible reaction with complex 13.
[0154] Example 9: Synthesis of dynamic epitope Conjugate 14 containing antigenic glycopeptide 14 of fibronectin glycoprotein as an additional dynamic epitope was synthesized. Conjugate 14 was synthesized according to the reaction scheme shown below.
[0155]
[0156] Complex 14 (SEQ ID NO: 6): (NEU1 inhibitor)- 2147 Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr(Siaα2,6GalNAcα1)-Thr(Siaα2,6GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg 2163 -Cys-NH2
[0157] The glycopeptide antigen 14 from the IIICS region of fibronectin glycoprotein was synthesized by Fmoc solid-phase peptide synthesis. The synthesis procedure consisted of sequential reactions using Rink Amide-ChemMatrix resin (0.42 mmol / g, 100 mg, 21 μmol) in a DMF solution containing Fmoc amino acid derivatives (84 μmol), HBTU (84 μmol), and HOBt (84 μmol) under microwave irradiation at 50°C, with each reaction lasting 10 min. Unreacted amino acids were acetylated by treatment with acetic anhydride / DIEA / DMF (v:v:v = 0.5:1:8.5) for 30 s at room temperature. The Fmoc group was deprotected by treatment with 20% piperidine / DMF for 3 min under microwave irradiation at 50°C.
[0158] The target peptide was synthesized by repeating these three steps: (A) elongation of various Fmoc amino acids, (B) acetylation of unreacted amino groups, and (C) de-Fmocation. However, at positions Thr2155 and Thr2156, instead of the usual Fmoc amino acid derivatives, Fmoc glycoamino acid derivatives containing a disaccharide (Sialyl-Tn) consisting of sialic acid and N-acetylgalactosamine were separately prepared by Enyu Pharma Co., Ltd. and used for the synthesis reaction.
[0159] After all amino acids and sugar amino acids were condensed, compound 9 (NEU1 sialidase inhibitor derivative 9) synthesized in Example 1 (1-2) was condensed to the N-terminal amino group under the same conditions as for Fmoc amino acid elongation. Furthermore, trifluoroacetic acid:water:ethanedithiol:tetraisopropylsilane (v:v:v:v = 94:2.5:2.5:1) was added to the reaction system, and the mixture was shaken at room temperature for 2 hours to simultaneously cleave the synthetic intermediate from the solid support and deprotect the side chains.
[0160] The reaction solution was filtered, tert-butylmethyl ether was added, and the mixture was centrifuged (5000 G, 4°C, 10 min). The supernatant was discarded, and the precipitate was dissolved in 50% acetonitrile and lyophilized to obtain the crude product of the desired conjugate 14. This lyophilized product was dissolved in methanol:water (v:v = 2:1), adjusted to pH 12.5 with 1 N sodium hydroxide, and shaken at room temperature for 1 hour to deprotect the acetyl groups in the glycan region. The solution was then neutralized with 30% acetic acid, and the solvent was removed under reduced pressure. The desired conjugate 14 was obtained by purification by reversed-phase high-performance liquid chromatography.
[0161]
[0162] MALDI-TOFMS: m / z calcd for C149H235F2N39O60S [MH]- 3599.615, found 3599.265.
[0163] In addition, a conjugate having the following non-glycosylated peptide (SEQ ID NO: 7) to be used for antibody screening was also synthesized in the same manner.
[0164]
[0165] MALDI-TOF MS: m / z calcd for C111H175F2N35O34S [MH]- 2611.265, found 2611.644.
[0166] Example 10: Synthesis of Dynamic Epitopes. Conjugate 14 prepared in Example 9 was conjugated with KLH (carrier protein) using the maleimidobenzoyloxysuccinimide (MBS) method to obtain a conjugate for antibody production. Approximately 0.1 mg of the resulting conjugate for antibody production was administered subcutaneously to the base of the tail of three mice (B6D2F1 / Slc) to elicit an immune response. A booster immunization was administered 17 days later using the same method, and blood was collected four days later. The iliac lymph nodes were then harvested. Lymphocytes collected from the harvested iliac lymph nodes were fused with myeloma cells SP2 and cultured in HAT selection medium to select antibody-producing cells.
[0167] Next, the culture supernatant of the obtained hybridoma was dispensed onto an ELISA plate, and positive wells were selected by binding to a bovine serum albumin (BSA)-glycopeptide antigen complex and a BSA-peptide antigen complex (a complex of BSA and the non-glycosylated peptide prepared in Example A), and screened by binding reactions with the dynamic epitope glycopeptide and the control non-glycosylated peptide.
[0168] The fused cells were cloned by limiting dilution and other methods. The binding specificity of the culture supernatants of single clones (subclones D-1 to D-5, subclones E-1 to E-4, and subclones F-1 to F-2) obtained from the three clone lineages of clone D, clone E, and clone F to glycopeptides (dynamic epitopes) is shown in Figures 8 and 9. These results demonstrate that the antibodies obtained from the culture supernatants of these clones bind only to glycopeptides and do not exhibit affinity for non-glycosylated peptides.
[0169] Example 11: Synthesis of glycopeptides with different glycosylation patterns and evaluation of antibody antigen recognition To examine the binding specificity of the monoclonal antibodies against fibronectin glycoproteins prepared in Example 10 to fibronectin glycopeptides, glycopeptides with different glycosylation patterns and non-glycosylated peptides were synthesized, and antigen recognition of antibodies in culture supernatants was evaluated by ELISA using compounds (or "substrates") conjugated to BSA.
[0170] First, the following six evaluation glycopeptides (SEQ ID NOs: 8 to 13) targeting the three putative glycosylation sites Thr2152, Thr2155, and Thr2156 of fibronectin glycoprotein were synthesized using Fmoc-Thr[Ac3Siaα(2→6)Ac2GalNAcα1→]-OH, Fmoc-Thr[Ac4Galβ(1→3)Ac2GalNAcα1→]-OH, or Fmoc-Thr[Ac3GalNAcα1→]-OH according to the solid-phase synthesis protocol for glycopeptide 14.
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177] Each synthesized glycopeptide was conjugated with BSA to prepare BSA-glycopeptide conjugates. 50 μL of PBS containing 1 μg / mL BSA-peptide conjugates was added to the wells of a nonspecifically adsorbent ELISA plate (Sumitomo Bakelite Co., Ltd.) and incubated overnight at 4°C. After discarding the solution and washing the wells with PBS, 100 μL of 1% BSA-containing PBS was added to the wells and incubated at room temperature for 2 hours to block the surface. After discarding the solution and washing the wells, each culture supernatant was diluted 10-fold, 30-fold, 100-fold, and 300-fold with ELISA buffer (25 mM Tris, 150 mM NaCl, 0.05% Tween-20, 0.1% BSA, pH 7.5), and 50 μL of each dilution was added to the plate and incubated at room temperature for 1 hour. The wells were then washed in the same manner, and 50 μL of anti-mouse IgG antibody AP conjugate (Promega) diluted 1 / 2500 in ELISA buffer was added and incubated for 1 hour at room temperature. The solution was discarded, and the wells were washed with PBS to completely remove the secondary antibody. 4-nitrophenol phosphate solution was then added, and the wells were incubated for 30 minutes at room temperature. The absorbance at 405 nm was measured using a plate reader.
[0178] The results are shown in Figures 10 and 11. Clone C, Clone D, and Clone E all strongly bound to glycopeptides with Sialyl-Tn attached at two sites, Thr2155 and Thr2156, but did not bind to glycopeptides with a different glycan modification (Tn or T) at the same sites or to glycopeptides with Sialyl-Tn attached at three sites, Thr2152, Thr2155, and Thr2156. This demonstrates that the antigen presentation method of the present invention produces highly antigen-specific antibodies that do not bind to glycopeptides with different glycan modification patterns.
[0179] SEQ ID NO: 1: Glycopeptide precursor 10 Gln-Val-Ser-Pro-Phe-Gly-Glu-Val-Phe-Asn(Fucα1,6GlcNAcβ1)-Ala-Thr-Arg-Phe-Ala-Ser-Val-Cys
[0180] SEQ ID NO: 2: Non-glycosylated peptide Gln-Val-Ser-Pro-Phe-Gly-Glu-Val-Phe-Asn-Ala-Thr-Arg-Phe-Ala-Ser-Val-Cys
[0181] SEQ ID NO: 3: Glycopeptide containing two glycosylation sites, Thr323 and Ser325, of the SARS-CoV-2 spike glycoprotein: Ser-Asn-Phe-Arg-Val-Gln-Pro-Thr(Galβ1,3GalNAcα1)-Glu-Ser(Galβ1,3GalNAcα1)-Ile-Val-Arg-Phe-Asn-Ile-Cys
[0182] SEQ ID NO: 4: Non-glycosylated peptide of SARS-CoV-2 spike glycoprotein Ser-Asn-Phe-Arg-Val-Gln-Pro-Thr-Glu-Ser-Ile-Val-Arg-Phe-Asn-Ile-Cys
[0183] SEQ ID NO: 5: MUC1-Tn glycopeptide Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(GalNAcα1)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala
[0184] SEQ ID NO: 6: Antigenic glycopeptide of fibronectin glycoprotein Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr(Siaα2,6GalNAcα1)-Thr(Siaα2,6GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Cys
[0185] SEQ ID NO: 7: Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr-Thr-Ala-Thr-Pro-Ile-Arg-His-Arg-Cys, an antigenic glycopeptide of fibronectin glycoprotein
[0186] SEQ ID NO: 8: Glycopeptide (2-SialylTn) of Example 11 His-Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr(Siaα2,6GalNAcα1)-Thr(Siaα2,6GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0187] SEQ ID NO: 9: Glycopeptide (3-SialylTn) for evaluation in Example 11 His-Gly-Phe-Arg-Arg-Thr-Thr(Siaα2,6GalNAcα1)-Pro-Pro-Thr(Siaα2,6GalNAcα1)-Thr(Siaα2,6GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0188] SEQ ID NO: 10: Glycopeptide (2-Tn) for evaluation in Example 11 His-Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr(GalNAcα1)-Thr(GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0189] SEQ ID NO: 11: Glycopeptide (3-Tn) for evaluation in Example 11: His-Gly-Phe-Arg-Arg-Thr-Thr(GalNAcα1)-Pro-Pro-Thr(GalNAcα1)-Thr(GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0190] SEQ ID NO: 12: Glycopeptide (2-Core1) for evaluation in Example 11 His-Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr(Galβ1,3GalNAcα1)-Thr(Galβ1,3GalNAcα1)-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0191] SEQ ID NO: 13: Glycopeptide for evaluation in Example 11 (Naked) His-Gly-Phe-Arg-Arg-Thr-Thr-Pro-Pro-Thr-Thr-Ala-Thr-Pro-Ile-Arg-His-Arg-Pro-Cys
[0192] The method of the present invention has made possible an MHC-independent antigen presentation method. This allows the glycan region of the "dynamic epitope" to be effectively recognized by B cells (inducing antigen-specific B cells) without being degraded, making it possible to produce antibodies that specifically bind to the "dynamic epitope," an antigen structure consisting of a target glycan and peptide, and dramatically improving the efficiency of producing such antibodies. Furthermore, by presenting the dynamic epitope on the surface of, for example, cancer cells, a method has been established for efficiently uptake by cancer cells of antibodies that bind to the dynamic epitope for cancer treatment.
Claims
1. A complex represented by the following formula (1): (In formula (1), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic moiety selected from glycoproteins and glycopeptides, CP is a carrier moiety, and X 1 and X 2 are each independently a single bond or a linking group.
2. In the formula (1), R 1 The complex according to claim 1 , wherein is a group represented by the following formula (2): (In formula (2), R 2 is a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms; R 3 is a hydrocarbon group having 1 to 12 carbon atoms, and * is the bonding site with the benzene ring in formula (1).
3. In the formula (2), R 2 The complex according to claim 2, wherein is a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms.
4. In the formula (2), R 3 The complex according to claim 2 or 3, wherein is an alkyl group having 1 to 3 carbon atoms.
5. The complex according to claim 1 or 2, wherein the carrier moiety is at least one selected from the group consisting of lipid nanoparticles, metal nanoparticles, polysaccharides and carrier proteins.
6. The conjugate of claim 1 or 2, which is used to bind to cells having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3).
7. The conjugate according to claim 1 or 2, which is used for producing antibodies.
8. A pharmaceutical composition comprising the complex according to claim 1 or 2.
9. The pharmaceutical composition according to claim 8, for use in the prevention and / or treatment of tumors and / or cancer.
10. A vaccine comprising the complex of claim 1 or 2.
11. A method for obtaining an antigen-presenting cell which presents the antigenic site and carrier site in formula (1) on the cell surface, comprising contacting a cell having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) with the complex described in claim 1 or 2.
12. A method for producing an antibody, comprising producing an antibody using the antigen-presenting cell described in claim 11.
13. A method for treating tumors and / or cancers, comprising administering a conjugate according to claim 1 or 2, and administering an antibody that binds to the antigenic site in formula (1).
14. Use of the complex according to claim 1 or 2 for the manufacture of a preventive and / or therapeutic agent for tumors and / or cancer.
15. A complex represented by the following formula (11): (In formula (11), R 1 is a neuraminic acid group or a neuraminic acid derivative group, DE is an antigenic site selected from glycoproteins and glycopeptides, X 1 and X 2 are each independently a single bond or a linking group.
16. In the formula (11), R 1 The complex according to claim 15 , wherein is a group represented by the following formula (2): (In formula (2), R 2 is a group containing at least one atom selected from the group consisting of carbon atoms, oxygen atoms, and nitrogen atoms and having 10 or less carbon atoms; R 3 is a hydrocarbon group having 1 to 12 carbon atoms, and * is the bonding site with the benzene ring in formula (1).
17. In the formula (2), R 2 The complex according to claim 16, wherein is a hydroxy group, an alkyl group having 1 to 6 carbon atoms, or an alkylamide group having 1 to 6 carbon atoms.
18. In the formula (2), R 3 The complex according to claim 16 or 17, wherein is an alkyl group having 1 to 3 carbon atoms.
19. A pharmaceutical composition comprising the conjugate of claim 15 or 16.
20. A method for obtaining an antigen-presenting cell which presents the antigenic site and carrier site in formula (11) on the cell surface, comprising contacting a cell having neuraminidase 1 (NEU1) or neuraminidase 3 (NEU3) with the complex described in claim 15 or 16.
Citation Information
Patent Citations
Method for synthesizing glycopeptide
JP2012167018A
Anti-MUC1 antibody
WO2010050528A1
Novel MUC1 antibody
WO2011135869A1
Neuraminidase inhibitor
US20070207971A1
Intracellular substance transport system and use thereof
WO2017131242A1
